Five years ago it was five times as many, but the widespread use of insecticide-treated bed nets and other strategies has dramatically reduced the annual number of deaths. However, mosquitoes evolve resistance to insecticides — which is why the Foundation for the National Institutes of Health (FNIH) has awarded almost $6 million to four teams to find new solutions to limit transmission of malaria.
Virginia Tech is represented among the four teams funded by the “New Insecticides for Malaria Control” program. Paul Carlier, professor of chemistry in the College of Science and a member of the Vector-Borne Disease Research Group at Virginia Tech, will receive $450,655 to work with Jeffrey Bloomquist, who will lead the effort to develop an entirely new strategy to kill the mosquito that transmits the malaria parasite.
Bloomquist, a member of the Emerging Pathogens Institute and the entomology and nematology departments at the University of Florida, has also enlisted Max Totrov, a protein modeler at Molsoft Corp. LLC, to assist in molecular design of the new insecticides. The total award, which is managed by the FNIH to the University of Florida, is $1.4 million over three years.
“Our team seeks to develop a new class of insecticide that will work by blocking potassium ion channels – specifically those involved in nerve signal transmission,” said Carlier. “If we can paralyze mosquitos, they will not be able to fly. If they cannot fly, they can’t bite. If they can’t bite, the malaria parasite cannot be passed to humans.”
No such insecticides exist. If the scientists succeed, the new compound would be safe and effective for use on bed nets. “Nets work for malaria control because malaria mosquitoes only bite at night,” said Carlier.
Bloomquist specializes in neuroscience and toxicology in animals and insects. Carlier specializes in organic and medicinal chemistry. This grant marks the fourth award for malaria research they have shared since 2005, including a National Institutes of Health-funded program that Carlier leads.
Since 2003, FNIH has worked with the Bill & Melinda Gates Foundation and other partners on the Grand Challenges in Global Health Initiative. In 2009, foundation received a five-year, $24 million grant to extend certain aspects of research initiated under the original initiative. The “Vector-based Control of Transmission: Discovery Research” program will continue to support the development of novel strategies to deplete or incapacitate disease-transmitting mosquito populations. The original announcement about the four new grant awards is posted on the FNIH website.
Established by the United States Congress to support the mission of the National Institutes of Health (NIH) — improving health through scientific discovery in the search for cures — the FNIH is a leader in identifying and addressing complex scientific and health issues. The foundation is a non-profit, 501(c)(3) charitable organization that raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities.
The Vector-Borne Disease Research Group at Virginia Tech is an initiative of the Fralin Life Science Institute.
Seven Virginia Tech institutes support research and creative scholarship in strategically important areas, drawing upon the university’s established strengths. The Virginia Tech Carilion School of Medicine and Research Institute, the Virginia Tech Transportation Institute, and the Virginia Bioinformatics Institute focus on national research priorities, including translational health and medical research, national security, and safe infrastructure. The Institute for Critical Technology and Applied Science, Fralin Life Science Institute, and the Institute for Society, Culture, and Environment provide organizational and financial support to develop opportunities at the intersection of engineering, science, and medicine; target infectious disease; and advance human development. The Institute for Creativity, Arts, and Technology promotes creativity, critical thinking, and life-long learning.